Extended Inhibition of Platelet Aggregation With the Orally Active Platelet Inhibitor SC-54684A

Abstract

The results of the dose-ranging study show that oral administration of SCp results in dose-dependent inhibition of platelet aggregation. As shown in the 14-day administration, this dose-dependent inhibition can be maintained for an extended period while exhibiting no adverse effects. SCp is a leading candidate for development and is currently in clinical trials.